Assessing the impact of levetiracetam and sodium valproate monotherapy on serum 25-hydroxy vitamin D levels in pediatric epilepsy: Insights from a leading tertiary care hospital in Haldwani

Background: Epilepsy, as a prevalent chronic neurological disorder, requires prolonged therapeutic interventions, which may expose pediatric patients undergoing anticonvulsant treatment to potential risks associated with Vitamin D deficiency and compromised bone health. This research delves into the impact of Levetiracetam (LEV) and Sodium Valproate (VPA), two commonly prescribed antiepileptic medications, on bone health. Aims and Objectives: To study the effects of LEV and sodium VPA monotherapy on serum 25-hydroxy vitamin D levels in pediatric patients with epilepsy (1–16 years). Materials and Methods: Within a prospective interventional investigation, a total of 148 newly diagnosed pediatric epilepsy patients aged between 1 and 16 years were recruited and segregated into two cohorts: One administered LEV (n=74) and the other receiving Sodium VPA (n=74). The study assessed serum Vitamin D levels, in conjunction with Calcium, Phosphorous, and ALP, both before and after a 6 months period of monotherapy. Results: Following the intervention, it was observed that 72.9% of patients treated with Sodium VPA demonstrated a decline in Vitamin D levels, among whom 24.3% displayed significant Vitamin D insufficiency (P<0.001). In contrast, 43.2% of individuals receiving LEV exhibited decreased Vitamin D levels, with only 6.2% manifesting Vitamin D insufficiency (P=0.004), indicating a comparatively milder impact on bone health. Conclusion: The findings suggest that Sodium VPA monotherapy substantially disrupts bone metabolism when juxtaposed with LEV, thus implying that the latter may represent a safer alternative concerning bone health. This study accentuates the critical importance of routine monitoring of Vitamin D levels and potential supplementation for pediatric patients undergoing treatment with Sodium VPA to alleviate the associated bone health hazards.

Authors

Institutions

Publication Details

Journal
Asian Journal of Medical Sciences
Published
2025-11-30
DOI
https://doi.org/10.71152/ajms.v16i12.4865
Primary Topic
Pharmacological Effects and Toxicity Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing the impact of levetiracetam and sodium valproate monotherapy on serum 25-hydroxy vitamin D levels in pediatric epilepsy: Insights from a leading tertiary care hospital in Haldwani

Ritu Rakholia, Pooja Agarwal, A.V. Siva Kumar, Y. K. Gupta
Asian Journal of Medical Sciences
Pharmacological Effects and Toxicity Studies
article

Assessing the impact of levetiracetam and sodium valproate monotherapy on serum 25-hydroxy vitamin D levels in pediatric epilepsy: Insights from a leading tertiary care hospital in Haldwani

Ritu Rakholia, Pooja Agarwal, A.V. Siva Kumar, Y. K. Gupta
article en

Abstract

Background: Epilepsy, as a prevalent chronic neurological disorder, requires prolonged therapeutic interventions, which may expose pediatric patients undergoing anticonvulsant treatment to potential risks associated with Vitamin D deficiency and compromised bone health. This research delves into the impact of Levetiracetam (LEV) and Sodium Valproate (VPA), two commonly prescribed antiepileptic medications, on bone health. Aims and Objectives: To study the effects of LEV and sodium VPA monotherapy on serum 25-hydroxy vitamin D levels in pediatric patients with epilepsy (1–16 years). Materials and Methods: Within a prospective interventional investigation, a total of 148 newly diagnosed pediatric epilepsy patients aged between 1 and 16 years were recruited and segregated into two cohorts: One administered LEV (n=74) and the other receiving Sodium VPA (n=74). The study assessed serum Vitamin D levels, in conjunction with Calcium, Phosphorous, and ALP, both before and after a 6 months period of monotherapy. Results: Following the intervention, it was observed that 72.9% of patients treated with Sodium VPA demonstrated a decline in Vitamin D levels, among whom 24.3% displayed significant Vitamin D insufficiency (P<0.001). In contrast, 43.2% of individuals receiving LEV exhibited decreased Vitamin D levels, with only 6.2% manifesting Vitamin D insufficiency (P=0.004), indicating a comparatively milder impact on bone health. Conclusion: The findings suggest that Sodium VPA monotherapy substantially disrupts bone metabolism when juxtaposed with LEV, thus implying that the latter may represent a safer alternative concerning bone health. This study accentuates the critical importance of routine monitoring of Vitamin D levels and potential supplementation for pediatric patients undergoing treatment with Sodium VPA to alleviate the associated bone health hazards.

Asian Journal of Medical SciencesVol. 16(12)
Government Medical College (IN)
Openalex Percentile: Top 52%
Pharmacological Effects and Toxicity Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.